Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carbamazepine
Drug ID BADD_D00356
Description Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.[L1335] Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.[A180319]
Indications and Usage Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia.[L1335] In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures.[A180301,L1335] Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder.[L1335] Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.[A180415,A180421]
Marketing Status approved; investigational
ATC Code N03AF01
DrugBank ID DB00564
KEGG ID D00252
MeSH ID D002220
PubChem ID 2554
TTD Drug ID D04MSM
NDC Product Code 62512-0024; 30698-421; 50268-172; 60687-583; 63629-9292; 66993-409; 70518-3266; 70771-1470; 0615-8125; 0781-5987; 0904-6885; 49452-1705; 63552-060; 0078-0510; 0078-0511; 16571-681; 16714-064; 0093-0778; 17856-0029; 29033-019; 30698-419; 35561-355; 50090-0384; 51672-4047; 51672-4151; 54092-173; 60429-934; 60687-594; 63629-8721; 70518-0181; 70771-1469; 70954-240; 71205-025; 75834-220; 12658-0525; 12658-0526; 0904-7116; 42419-014; 35561-357; 51672-4149; 54092-171; 59746-789; 60505-2805; 63629-8743; 66993-407; 67386-621; 68788-7210; 70518-1433; 59746-790; 63629-8753; 68084-562; 68382-557; 70518-3176; 0781-5988; 16714-063; 27241-233; 29033-004; 29300-382; 35561-356; 51407-215; 60505-2807; 70518-1545; 71930-073; 72162-2021; 0781-8016; 0832-6022; 12658-0561; 12658-0565; 48087-0051; 70966-0020; 76003-0251; 13668-268; 0093-0109; 27241-232; 43063-328; 50268-170; 54092-172; 60505-2806; 68788-7825; 70518-1436; 70518-2242; 70518-3335; 71335-0461; 71335-0691; 71930-072; 75834-221; 0904-3854; 51927-2176; 13668-271; 51672-4125; 63629-8715; 68084-444; 68382-555; 70518-1769; 70518-2456; 70518-3699; 70518-3773; 0832-6023; 12658-0452; 51552-0653; 62991-1027; 65344-0028; 65344-0040; 0078-0512; 27241-231; 0121-0947; 43353-953; 59746-791; 70518-2426; 70518-3146; 71930-074; 72189-157; 0904-6172; 12658-0406; 12658-0541; 0078-0509; 0093-0090; 29033-020; 51672-4005; 51672-4123; 55154-1396; 60505-0183; 60687-479; 63629-8720; 68094-007; 68382-556; 70518-2841; 70518-3591; 70518-3694; 71335-1730; 12658-0486; 38779-0114; 48087-0052; 0078-0508; 16714-065; 30698-423; 50268-171; 51672-4150; 58118-0268; 66993-408; 68071-2701; 70518-2489; 70518-3174; 70771-1468; 0615-3505; 72664-218; 0832-6024; 65372-1102; 16571-680; 16571-682; 0121-1894; 50090-5740; 51672-4041; 51672-4124; 60429-032
UNII 33CM23913M
Synonyms Carbamazepine | Carbamazepine Acetate | Carbamazepine Dihydrate | Carbamazepine Hydrochloride | Carbamazepine L-Tartrate (4:1) | Carbamazepine Anhydrous | Carbamazepine Sulfate (2:1) | Carbazepin | Epitol | Finlepsin | Neurotol | Tegretol | Amizepine | Carbamazepine Phosphate
Chemical Information
Molecular Formula C15H12N2O
CAS Registry Number 298-46-4
SMILES C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Altered pitch perception17.02.03.018; 19.21.01.0110.000409%-
Anisocoria06.05.03.013; 17.02.11.0090.000186%-
Attention deficit hyperactivity disorder19.21.04.0040.000744%-
B-cell aplasia01.02.02.0060.000186%-
Behaviour disorder19.01.01.0050.000558%-
Blood loss anaemia01.03.02.018; 24.07.01.0880.000372%-
Cross sensitivity reaction10.01.01.0360.000372%-
Cytotoxic lesions of corpus callosum12.03.01.062; 17.02.10.0300.000372%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.002---
Electric shock sensation08.06.02.023; 17.02.07.024---
Epileptic encephalopathy17.12.03.033; 19.21.02.0150.000186%-
Eye symptom06.08.03.027; 17.17.02.0150.000186%-
Fixed eruption08.01.06.025; 10.01.01.037; 23.03.05.0080.000279%-
Focal dyscognitive seizures17.12.02.0050.000558%-
Follicular mucinosis23.02.02.0110.000409%-
Gait inability08.01.02.011; 17.02.05.0690.000651%-
Gallbladder oedema09.03.02.0110.000186%-
Haemophagocytic lymphohistiocytosis01.05.01.026; 10.02.01.077; 16.32.03.0380.000558%-
Hepatic cytolysis09.01.07.0360.000279%-
Hyperchromic anaemia01.03.02.0200.000186%-
Hyperleukocytosis01.02.01.0180.000186%-
Immune thrombocytopenia01.08.01.013; 10.02.01.0830.000558%-
Lennox-Gastaut syndrome17.12.03.013; 19.21.02.0060.000186%-
Mucosal disorder08.01.06.0290.000465%-
Negative symptoms in schizophrenia19.03.04.0020.000186%-
Periorbital swelling06.08.03.032; 10.01.05.025; 23.04.01.0250.000186%-
Pharyngeal swelling22.04.05.0280.000186%-
Potentiating drug interaction08.06.03.0150.000186%-
Pregnancy on contraceptive18.08.01.0040.000186%-
Pregnancy on oral contraceptive18.08.01.0050.000186%-
The 31th Page    First    Pre   31 32    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene